Simcere Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yunshu Zhou

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yunshu Zhou (53 yo)

less than a year

Görev süresi

Dr. Yunshu Zhou is Chief Executive Officer at Simcere Pharmaceutical Group Limited since March 25, 2026. He has experience in research and development and commercialization within the pharmaceutical indust...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jinsheng Ren	Co-Founder & Chairman	10.4yrs	CN¥5.06m	4.8% $ 219.2m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	6.4yrs	CN¥2.17m	0.056% $ 2.6m
Renhong Tang	Executive Director	3.3yrs	CN¥56.85m	0.060% $ 2.7m
Xi Wang	VP & Executive Director	3.3yrs	CN¥2.02m	Veri yok
Yunshu Zhou	Chief Executive Officer	less than a year	Veri yok	Veri yok
Gaobo Zhou	Chief Investment Officer	4.3yrs	Veri yok	Veri yok
Quanfu Feng	Vice President of Marketing	no data	Veri yok	Veri yok
Tamas Oravecz	Senior VP & Chief Scientific Officer of Simcere Zaiming	3.6yrs	Veri yok	Veri yok
Aik Han Goh	Senior VP & Chief Medical Officer	2.3yrs	Veri yok	Veri yok
Yongyu Wang	Senior VP & Chief Medical Officer of Simcere Zaiming	1.8yrs	Veri yok	Veri yok
Wang Felix	Senior VP & Secretary of the Party Committee	2.3yrs	Veri yok	Veri yok
Po Man Mak	Joint Company Secretary	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: SMHG.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jinsheng Ren	Co-Founder & Chairman	10.4yrs	CN¥5.06m	4.8% $ 219.2m
Yushan Wan	CFO, Joint Company Secretary & Executive Director	6.4yrs	CN¥2.17m	0.056% $ 2.6m
Renhong Tang	Executive Director	6.4yrs	CN¥56.85m	0.060% $ 2.7m
Xi Wang	VP & Executive Director	3.3yrs	CN¥2.02m	Veri yok
Jianguo Wang	Independent Non-Executive Director	6.4yrs	CN¥360.00k	Veri yok
Xinhua Wang	Independent Non-Executive Director	6.4yrs	CN¥360.00k	Veri yok
Ruilin Song	Independent Non-Executive Director	6.4yrs	CN¥360.00k	Veri yok
Ka Woon Sung	Independent Non-Executive Director	3.3yrs	CN¥360.00k	Veri yok

6.4yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SMHG.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/17 09:51
Gün Sonu Hisse Fiyatı	2026/03/09 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Simcere Pharmaceutical Group Limited 16 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Shaojing Tong	BofA Global Research
Bo Yu	China International Capital Corporation Limited
null null	CMB International Securities Limited

Simcere Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 12, 2026

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 13, 2025

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Recent updates

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 12, 2026

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 25, 2026

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 247,469,761 shares, representing 10% of its issued share capital, under the authorization approved on June 13, 2025.

Simcere's IL-2 Mutant Fusion Protein Sim0278 Enters Phase II Clinical Trial Stage

Simcere Pharmaceutical Group Limited has completed a Follow-on Equity Offering in the amount of HKD 1.56695 billion.

Simcere Pharmaceutical Group Limited has filed a Follow-on Equity Offering in the amount of HKD 1.56695 billion.

Simcere Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 21, 2025

Connect Biopharma Holdings Limited Announces Submission of Its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China

Simcere Pharmaceutical Group Limited and Connect Biopharma Hongkong Limited Accepts New Drug Application of Rademikibart

Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Enzeshu®? in China by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval for Marketing of QUVIVIQ in China by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2024, Payable on or Before July 14, 2025

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval from National Medical Products Administration

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 13, 2025

Simcere Pharmaceutical Group Limited Announces That New Drug Application of Deunoxavir Marboxil Tablets Was Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 24, 2025

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for Sim0505 (CDH6 Antibody-Drug Conjugate) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List

Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference

Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024.

Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China

Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

CEO